This trial is testing a new drug, SNDX-5613, to see if it is safe and effective when given with chemotherapy to people with leukemia that has come back or does not respond to treatment.
- Relapsed/Refractory Leukemias
- Mixed Phenotype Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
2 Primary · 3 Secondary · Reporting Duration: Day 1 through up to 30 days after last dose of study intervention
2 Treatment Groups
SNDX-5613 and Chemotherapy Regimen 2
1 of 2
SNDX-5613 and Chemotherapy Regimen 1
1 of 2
54 Total Participants · 2 Treatment Groups
Primary Treatment: SNDX-5613 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age Any Age · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are engaged in this clinical experimentation?
"Affirmative. According to the information found on clinicaltrials.gov, recruitment for this medical trial is ongoing since its initial posting date of March 9th 2022 and last updated on July 18th 2022. Currently, 54 participants are being sought from 2 participating facilities." - Anonymous Online Contributor
Has the FDA sanctioned SNDX-5613 for use?
"Our team at Power scored SNDX-5613 with a 1 on the safety scale as this is an early Phase 1 trial, so there are limited published data to demonstrate its efficacy and security." - Anonymous Online Contributor
Are there still vacancies available for volunteers in this clinical trial?
"Clinicaltrials.gov states that the study is actively searching for participants, with its initial posting being made on March 9th 2022 and a subsequent update occurring on July 18th 2022." - Anonymous Online Contributor